Journal article
The impact of HLA class I and EBV latency-II antigen-specific CD8 T cells on the pathogenesis of EBV Hodgkin lymphoma
K Jones, L Wockner, RM Brennan, C Keane, PK Chattopadhyay, M Roederer, DA Price, DK Cole, B Hassan, K Beck, D Gottlieb, DS Ritchie, JF Seymour, F Vari, P Crooks, SR Burrows, MK Gandhi
Clinical and Experimental Immunology | WILEY | Published : 2016
DOI: 10.1111/cei.12716
Abstract
In 40% of cases of classical Hodgkin lymphoma (cHL), Epstein-Barr virus (EBV) latency-II antigens [EBV nuclear antigen 1 (EBNA1)/latent membrane protein (LMP)1/LMP2A] are present (EBV+cHL) in the malignant cells and antigen presentation is intact. Previous studies have shown consistently that HLA-A*02 is protective in EBV+cHL, yet its role in disease pathogenesis is unknown. To explore the basis for this observation, gene expression was assessed in 33 cHL nodes. Interestingly, CD8 and LMP2A expression were correlated strongly and, for a given LMP2A level, CD8 was elevated markedly in HLA-A*02- versus HLA-A*02+ EBV+cHL patients, suggesting that LMP2A-specific CD8+ T cell anti-tumoral immunity..
View full abstractGrants
Awarded by National Institute of Allergy and Infectious Diseases
Funding Acknowledgements
This study was conducted under the auspices of the Australasian Leukaemia and Lymphoma Group. K. J. and C. K. were supported by the Leukaemia Foundation (Australia). M. K. G. is supported by the Leukaemia Foundation of Queensland. D. A. P. is a Wellcome Trust Senior Investigator. S. R. B is an NHMRC Principal Research Fellow (APP1021452).